

EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) AT 69TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Eisai will present the latest data on its in-house developed AMPA receptor antagonist Fycompa® (perampanel hydrate, perampanel) will be presented at the 69th American Epilepsy Society (AES) Annual Meeting to be held from December 4 to 8 in Philadelphia in the United States.

For this year's AES meeting, poster presentations will be given on 22 abstracts with highlights including additional and pooled analyses on the results of global Phase III clinical studies on primary generalized tonic-clonic (PGTC) seizures in patients with generalized epilepsy (Study 332) and on partial-onset epilepsy (Study 304, Study 305, Study 306), as well as the results of a Phase III clinical study on partial-onset epilepsy conducted in Asia including Japan. Furthermore, the overall results of Study 332

Abstract number	Abstract title
Abstract number: #1.196 <i>Saturday December 5</i> <i>Poster presentation: 12:00-18:00</i> <i>Poster discussion: 12:00-14:00</i>	Long-